Skip to main content
CStone Pharmaceuticals logo

CStone Pharmaceuticals — Investor Relations & Filings

Ticker · 2616 ISIN · KYG2588M1006 LEI · 300300095A57F80T2461 HKEX Manufacturing
Open in API
Filings indexed 3,374 across all filing types
Latest filing 2022-04-29 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 2616

About CStone Pharmaceuticals

http://www.cstonepharma.com

CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the research, development, and commercialization of anti-tumor drugs. The company is dedicated to addressing the unmet medical needs of cancer patients globally. Its core therapeutic focus is on innovative immuno-oncology and molecularly targeted therapies. The R&D pipeline is strategically balanced, featuring potential first-in-class or best-in-class assets, including Antibody-Drug Conjugates (ADC) and multi-specific antibodies. CStone has successfully launched four innovative drugs and secured multiple New Drug Application and indication approvals.

Recent filings

Filing Released Lang Actions
(1) DISCLOSEABLE AND CONTINUING CONNECTED TRANSACTION PROVISION OF FINANCIAL SERVICES TO SHANDONG ENERGY AND (2) REVISION OF ANNUAL CAPS FOR CONTINUING CONNECTED TRANSACTIONS
Regulatory Filings Classification · 95% confidence The document is an announcement related to continuing connected transactions between Yankuang Energy Group Company Limited and Shandong Energy, including the provision of financial services and revision of annual caps for these transactions. It references compliance with the Listing Rules, details of agreements, and the need for shareholder approval and circulars. The content is regulatory in nature, focusing on disclosures about connected transactions and compliance with stock exchange rules, rather than financial results, management changes, or other report types. It is not a full financial report, earnings release, or management discussion, but a regulatory announcement about connected transactions and related approvals. Therefore, it fits best under Regulatory Filings (RNS).
2022-04-29 English
RESULTS REPORT FOR THE FIRST QUARTER OF 2022
Interim / Quarterly Report Classification · 100% confidence The document is titled 'RESULTS REPORT FOR THE FIRST QUARTER OF 2022' and contains detailed unaudited financial data for the first quarter ending March 31, 2022. It includes major financial data, financial indicators, profit and loss items, changes in financial data, and shareholder information. The report is prepared according to quarterly disclosure regulations and accounting standards. The length is substantial (15,000 characters), and it contains actual financial statements and analysis for a period shorter than a full fiscal year. This matches the definition of an Interim / Quarterly Report (IR). Q1 2022
2022-04-29 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2022-04-29 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2022-04-29 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2022-04-29 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 95% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2022-04-29 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.